Acquiring Company
Charles River Laboratories
Acquired Company
K.F
Wilmington
CambodiaBiotechnologyHealth CareScience And EngineeringPharmaceuticalBiotechnologyPharmaceuticalDescription
Charles River Laboratories announced the acquisition of Cambodia-based NHP-supplier K.F. for approximately $510 million. This acquisition is expected to enhance the company's supply chain and contribute positively to per share profit. Furthermore, it aims to add 25 cents to per share profit this year and around 60 cents in 2027. The acquisition aligns with Charles River's growth strategy in the biopharmaceutical industry.
Who to call at Charles River Laboratories, and when
When Charles River Laboratories changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Charles River Laboratories raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Charles River Laboratories, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Charles River Laboratories. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Charles River Laboratories makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired K.F?
K.F was acquired by Charles River Laboratories, based in Wilmington. The deal was reported on February 19, 2026. Charles River Laboratories is a leading provider of drug development services. The company specializes in preclinical and clinical laboratory services for the pharmaceutical and biotechnology industries. Charles River Laboratories is publicly traded (CRL) and operates in Biotechnology.
When did Charles River Laboratories acquire K.F?
Charles River Laboratories's acquisition of K.F was reported on February 19, 2026. Charles River Laboratories announced the acquisition of Cambodia-based NHP-supplier K.F. for approximately $510 million. This acquisition is expected to enhance the company's supply chain and contribute positively to per share profit. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does K.F do?
K.F. is a supplier of non-human primates for various research purposes. The company plays a crucial role in supporting drug development processes. By providing quality biological materials, it enables pharmaceutical companies in their research efforts. K.F. It is privately held, operating in Biotechnology, and is based in Cambodia.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.